The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...

Some outcomes, like reduced risk of cardiovascular disease and increased chance of nausea, were expected. But others took ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Topiramate, primarily used for epilepsy and migraine prevention, is emerging as a cost-effective treatment for weight loss ...

The Biden administration said Medicare will negotiate discounts with drug companies on 15 drugs prescribed to treat cancer, ...